The Osteoinductive Effect of Controlled Bone Morphogenic Protein 2 Release Is Location Dependent

Maurits G.L. Olthof, Lichun Lu, Marianna A. Tryfonidou, Loek D. Loozen, Behdad Pouran, Michael J. Yaszemski, Björn P. Meij, Wouter J.A. Dhert, Jacqueline Alblas, Diederik H.R. Kempen

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The main challenge in bone morphogenic protein 2 (BMP-2)-based application lies in finding strategies that prolong its effective period as it has a short biological half-life. Several BMP-2 release profiles have shown to enhance bone formation at various application sites. However, it remains to be determined which BMP-2 release profile best augments bone formation and whether this effect is location dependent. Therefore, the aim of this study was to investigate the effect of BMP-2 release from oligo[(polyethylene glycol) fumarate] bis(2-(methacryloyloxy)ethyl) phosphate (OPF-BP) composites on the osteoinductive efficacy at ectopic versus orthotopic application. By varying the BMP-2 loading method, three different OPF-BP composites were created with varied release profiles. The composites were compared with unloaded OPF-BP as negative control, and to the clinically used Infuse ® absorbable collagen sponge (ACS) as positive control. Bone formation was assessed by microcomputed tomography after 9 weeks of subcutaneous implantation and 3, 6, and 9 weeks of orthotopic implantation in rats (n = 48). Whereas a BMP-2 burst release of >49% generated significantly more bone compared with sustained release (burst release <30%) at the subcutaneous implantation site, differential release did not affect bone formation at the orthotopic site. Furthermore, all BMP-2 containing OPF-BP composites showed significantly more bone formation compared with ACS in the orthotopic implantation site. In conclusion, this study clearly shows that the osteoinductive effect of different BMP-2 release profiles is location dependent. In addition, more bone formation in OPF-BP compared with ACS at both application sites emphasizes the role of biomaterials as a scaffold to achieve proper bone tissue formation. The main challenge in bone morphogenic protein 2 (BMP-2)-based application lies in finding strategies to prolong its biologic activity as it has a short biological half-life. The present study uses a phosphate-modified oligo[(polyethylene glycol) fumarate] hydrogel that can be tuned to achieve differential release profiles of biologically active BMP-2 release. We demonstrate that this platform outperforms Infuse ® , currently used in the clinic and that the osteoinductive effect of BMP-2 is location dependent. Altogether, this study stresses the importance of evaluating efficacy of bone tissue engineering strategies at an orthotopic location rather than subcutaneously. Even more so, it emphasizes the role of biomaterials as a scaffold to achieve proper bone tissue engineering.

Original languageEnglish (US)
Pages (from-to)193-202
Number of pages10
JournalTissue Engineering - Part A
Volume25
Issue number3-4
DOIs
StatePublished - Feb 2019

Keywords

  • application sites
  • bone morphogenetic protein 2
  • bone tissue engineering
  • oligo[(polyethylene glycol) fumarate]

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials

Fingerprint

Dive into the research topics of 'The Osteoinductive Effect of Controlled Bone Morphogenic Protein 2 Release Is Location Dependent'. Together they form a unique fingerprint.

Cite this